These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15902440)

  • 1. Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes.
    van Schaijk FG; Boerman OC; Soede AC; McBride WJ; Goldenberg DM; Corstens FH; Oosterwijk E
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1089-95. PubMed ID: 15902440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
    Peräalä-Heape M; Vihko P; Vihko R
    Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
    Boerman OC; Kranenborg MH; Oosterwijk E; Griffiths GL; McBride WJ; Oyen WJ; de Weijert M; Oosterwijk-Wakka J; Hansen HJ; Corstens FH
    Cancer Res; 1999 Sep; 59(17):4400-5. PubMed ID: 10485489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
    Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
    Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies.
    Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
    Int J Cancer; 1998 Jan; 75(1):74-80. PubMed ID: 9426693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
    Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
    Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
    Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
    Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
    Karacay H; McBride WJ; Griffiths GL; Sharkey RM; Barbet J; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2000; 11(6):842-54. PubMed ID: 11087333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.
    Patil V; Gada K; Panwar R; Varvarigou A; Majewski S; Weisenberger A; Ferris C; Tekabe Y; Khaw BA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):824-39. PubMed ID: 22302089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
    Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.